Klein, Christian

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 4,661

A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Thommen, D. S., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., et al. (2018) · Nature Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,161

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation

Angiogenesis and VEGF in CancerCell Adhesion Molecules Research

Cited by 479

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection

Monoclonal and Polyclonal Antibodies ResearchProtein purification and stability

Cited by 425

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 394

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 366

STAT3 Is Required for IL-6-gp130–Dependent Activation of Hepcidin In Vivo

Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., & Trautwein, C. (2007) · Gastroenterology

Iron Metabolism and DisordersCytokine Signaling Pathways and Interactions

Cited by 315

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 281

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 204

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research

Angiogenesis and VEGF in CancerMonoclonal and Polyclonal Antibodies Research

Cited by 201

Lack of gp130 expression in hepatocytes promotes liver injury1 1K.L.S. and T.W. contributed equally to this work.

StreetZ, K. L., Wüstefeld, T., Klein, C., Kallen, K.-J., Tronche, F., Betz, U. A. K., Schütz, G., Manns, M. P., Müller, W., & Trautwein, C. (2003) · Gastroenterology

Cytokine Signaling Pathways and InteractionsLiver physiology and pathology

Cited by 94

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife

3D Printing in Biomedical ResearchImmunotoxicology and immune responses

Cited by 82

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

Leclercq-Cohen, G., Steinhoff, N., Albertí Servera, L., Nassiri, S., Danilin, S., Piccione, E., Yángüez, E., Hüsser, T., Herter, S., Schmeing, S., et al. (2023) · Clinical Cancer Research

CAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research

Cited by 65

ME3738 protects from concanavalin A‐induced liver failure via an IL‐6‐dependent mechanism

Klein, C., Wüstefeld, T., Heinrich, P. C., Streetz, K. L., Manns, M. P., & Trautwein, C. (2003) · European Journal of Immunology

Drug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

Cited by 27

Contribution of Interleukin‐6/gp130 Signaling in Hepatocytes to the Inflammatory Response in Mice Infected with Streptococcus pyogenes

Klein, C., Medina, E., Sander, L., Dierssen, U., Roskams, T., Mueller, W., Trautwein, C., & Goldmann, O. (2007) · The Journal of Infectious Diseases

Sepsis Diagnosis and TreatmentCytokine Signaling Pathways and Interactions

Cited by 11